A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

(2021) Laura Katharina Schmalbrock et al.   BLOOD

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

(2021) Frank G. Rücker et al.   LEUKEMIA

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target

(2020) Andrea Ghelli Luserna di Rorà et al.   Journal of Hematology & Oncology

Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation

(2018) Alissa Marhäll et al.   ANNALS OF HEMATOLOGY

Pattern and prognostic value of FLT3 -ITD mutations in Chinese de novo adult acute myeloid leukemia

(2018) Song-Bai Liu et al.   CANCER SCIENCE

15 years of PhosphoSitePlus®: integrating post-translationally modified sites, disease variants and isoforms

(2018) Peter V Hornbeck et al.   NUCLEIC ACIDS RESEARCH

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional characterization of somatic mutations in cancer using network-based inference of protein activity

(2016) Mariano J Alvarez et al.   NATURE GENETICS

Targeting WEE1 Kinase in Cancer

(2016) Christopher J. Matheson et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo

(2015) P Arreba-Tutusaus et al.   LEUKEMIA

SIGNOR: a database of causal relationships between biological entities

(2015) Livia Perfetto et al.   NUCLEIC ACIDS RESEARCH

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation

(2014) R. F. Schlenk et al.   BLOOD

Human Cdc14A regulates Wee1 stability by counteracting CDK-mediated phosphorylation

(2012) Sara Ovejero et al.   MOLECULAR BIOLOGY OF THE CELL

Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1

(2012) Marieke Aarts et al.   Cancer Discovery

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications

(2011) Shinichiro Takahashi   Journal of Hematology & Oncology

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome

(2009) S. Kayser et al.   BLOOD

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML

(2009) F. Breitenbuecher et al.   BLOOD

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS